Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | HMGCR | P04035 | 1/20 | 0.30 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.30 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10308674 | 1.00 | ALDH1A1 (0.44) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL10308376 | 0.91 | ALDH1A1 (0.52) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL20207372 | 0.85 | ALDH1A1 (0.65) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL5145947 | 0.84 | ALDH1A1 (0.60) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL13043706 | 0.83 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL11986244 | 0.78 | ALDH1A1 (0.75) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL13043705 | 0.78 | ALDH1A1 (0.31) | ALDH1A1TDP1 | |
| SCHEMBL12477350 | 0.73 | ALDH1A1 (0.46) | ALDH1A1KDM4ELMNAMAPTALOX15 | |
| SCHEMBL5665588 | 0.73 | ALDH1A1 (0.46) | ALDH1A1LMNATSHRTDP1HMGCR | |
| SCHEMBL13113820 | 0.72 | ALDH1A1 (0.46) | ALDH1A1KDM4ELMNAMAPTALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | FRANKLIN RICHARD (GB) | 2012-08-09 | — | — | US | disclosed |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | SHIRE LLC (US) | 2011-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202756-A1 | USE OF PRODRUGS TO AVOID GI MEDIATED ADVERSE EVENTS | OPRM1, UGT1A6, UGT1A4 | ALDH1A1 327/4885KDM4E 2296/4885LMNA 4530/4885 |
| US-20120178666-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | ALDH1A1 677/4885KDM4E 1653/4885LMNA 4311/4885 |
| US-20110065796-A1 | PRODRUGS OF GUANFACINE | DNPEP, VIP, GDA | ALDH1A1 677/4885KDM4E 1653/4885LMNA 4311/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.